This is Akafou’s Linked In post and image from 28 March 2026,
Let’s be direct: combustion is outdated.
The conversation is no longer about whether people will consume. It’s about how they consume — and who controls that experience.
Here’s how the market is structurally evolving across three distinct use cases:
1. Wellness → controlled inhalation, no combustion
Objective: relaxation, focus, recovery
The shift is already happening toward vaporization of standardized cannabis (CBD / CBG dominant profiles): – Temperature-controlled delivery – Preservation of terpenes and full-spectrum effects –
Reduced exposure to combustion by-products This is not about “healthy consumption.”
This is about risk reduction and product intelligence.
2. Medical → precision-driven delivery
Objective: treat, stabilize, dose accurately
The real disruption is here: – Metered-dose inhalers delivering exact cannabinoid ratios – Fast onset with high reproducibility – Pharmaceutical-grade standards (GMP, clinical validation);
This is the transition from informal use to engineered cannabinoid therapeutics.
3. Adult use → optimized experience
Objective: pleasure, social use, controlled intensity
Alternatives are scaling fast: – Dry herb vaporizers – Vape cartridges (distillate / rosin + terpene profiles);
Key advantages: – Reduced odor – Lower irritation – Precise control over dosage and effect
What’s actually happening
The winners in this market won’t be those selling volume. They will be those building inhalation systems:
– Standardized inputs
– Controlled delivery
– Transparent composition
Combustion is inefficient, inconsistent, and impossible to standardize.
Technology fixes all three.
My conviction:
The future of cannabis is not flower vs oil. It’s not medical vs recreational. It’s combustion vs controlled inhalation. And controlled inhalation is already winning.
#
